ArticleRadiology case reports2025
Primary hepatic squamous cell carcinoma with pseudoachalasia treated with TACE: Case report and literature review.
Article in Radiology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary hepatic squamous cell carcinoma (PHSCC), an exceptionally rare subtype of primary liver cancer, has been documented in fewer than 200 cases worldwide. Its diagnosis presents formidable challenges due to the absence of pathognomonic features, and it is frequently associated with an unfavorable prognosis. In this case, a 66-year-old female exhibited progressive dysphagia persisting for three months. A comprehensive diagnostic workup encompassing liver biopsy, contrast-enhanced abdominal CT, dual-phase gastrointestinal radiography, gastroduodenoscopy, and FDG-PET/CT confirmed PHSCC coexisting with secondary pseudoachalasia. To mitigate tumor burden and relieve extrinsic compression on the gastroesophageal junction, transarterial chemoembolization (TACE) targeting the left hepatic lesion was administered, utilizing a combination of chemotherapeutic agents (albumin-bound paclitaxel and cisplatin) and embolic microspheres. Given the lack of consensus guidelines for this orphan disease, advancing diagnostic precision and therapeutic innovations is imperative to optimize clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.